A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

British Journal of Haematology

Volumn 165, Issue 6, 2014, Pages 768-776

  Ogura, Michinori ^a   Ando, Kiyoshi ^b   Suzuki, Tatsuya ^a   Ishizawa, Kenichi ^c   Oh, Sung Yong ^d   Itoh, Kuniaki ^e   Yamamoto, Kazuhito ^f   Au, Wing Yan ^g   Tien, Hwei Fang ^h   Matsuno, Yoshihiro ⁱ   Terauchi, Takashi ^j   Yamamoto, Keiko ^k   Mori, Masahiko ^k   Tanaka, Yoshinobu ^k   Shimamoto, Takashi ^k   Tobinai, Kensei ^j   Kim, Won Seog ^l  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHOKU UNIVERSITY HOSPITAL   (Japan)

^d Dong A University College of Medicine   (South Korea)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g QUEEN MARY HOSPITAL   (Hong Kong)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^j NATIONAL CANCER CENTER HOSPITAL   (Japan)

^k Merck Sharp Dohm Res Labs Japan   (Japan)

^l Sungkyunkwan University School of Medicine   (South Korea)

more..

Author keywords

Follicular lymphoma; HAT mutation; Indolent B cell non Hodgkin lymphoma; Phase II trial; Vorinostat

Indexed keywords

RITUXIMAB; VORINOSTAT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; CREBBP GENE; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EP300 GENE; FATIGUE; FEMALE; GENE; GENE MUTATION; HUMAN; HYPERGLYCEMIA; INDOLENT B CELL NONHODGKIN LYMPHOMA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

FOLLICULAR LYMPHOMA; HAT MUTATION; INDOLENT B-CELL NON-HODGKIN LYMPHOMA; PHASE II TRIAL; VORINOSTAT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CREB-BINDING PROTEIN; DNA MUTATIONAL ANALYSIS; E1A-ASSOCIATED P300 PROTEIN; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MUTATION; NEOPLASM GRADING; RECURRENCE; TREATMENT OUTCOME;

EID: 84901696903     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12819     Document Type: Article

References (20)

1. Bali, P., Pranpat, M., Swaby, R., Fiskus, W., Yamaguchi, H., Balasis, M., Rocha, K., Wang, H.G., Richon, V. & Bhalla, K. (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clinical Cancer Research, 11, 6382-6389.
2. Carlisi, D., Vassallo, B., Lauricella, M., Emanuele, S., D'Anneo, A., Di Leonardo, E., Di Fazio, P., Vento, R. & Tesoriere, G. (2008) Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. International Journal of Oncology, 32, 177-184.
3. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244-1253.
4. Glaser, K.B., Li, J., Pease, L.J., Staver, M.J., Marcotte, P.A., Guo, J., Frey, R.R., Garland, R.B., Heyman, H.R., Wada, C.K., Vasudevan, A., Michaelides, M.R., Davidsen, S.K. & Curtin, M.L. (2004) Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochemical and Biophysical Research Communications, 325, 683-690.
5. Kahl, B.S., Bartlett, N.L., Leonard, J.P., Chen, L., Ganjoo, K., Williams, M.E., Czuczman, M.S., Robinson, K.S., Joyce, R., van der Jagt, R.H. & Cheson, B.D. (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer, 116, 106-114.
6. Kirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, V., Matsuoka, D., Pulone, B., Rotter, A.J., Espinoza-Delgado, I., Nademanee, A., Forman, S.J., Gandara, D. & Newman, E. (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 29, 1198-1203.
7. Morin, R.D., Mendez-Lago, M., Mungall, A.J., Goya, R., Mungall, K.L., Corbett, R.D., Johnson, N.A., Severson, T.M., Chiu, R., Field, M., Jackman, S., Krzywinski, M., Scott, D.W., Trinh, D.L., Tamura-Wells, J., Li, S., Firme, M.R., Rogic, S., Griffith, M., Chan, S., Yakovenko, O., Meyer, I.M., Zhao, E.Y., Smailus, D., Moksa, M., Chittaranjan, S., Rimsza, L., Brooks-Wilson, A., Spinelli, J.J., Ben-Neriah, S., Meissner, B., Woolcock, B., Boyle, M., McDonald, H., Tam, A., Zhao, Y., Delaney, A., Zeng, T., Tse, K., Butterfield, Y., Birol, I., Holt, R., Schein, J., Horsman, D.E., Moore, R., Jones, S.J., Connors, J.M., Hirst, M., Gascoyne, R.D. & Marra, M.A. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature, 476, 298-303.
8. Ogura, M., Morishima, Y., Kobayashi, Y., Uike, N., Sugai, S., Chou, T., Kasai, M., Miura, I., Murayama, T., Matsuno, Y., Nakamura, S., Mori, S., Ohashi, Y., Tobinai, K. & Cladribine Study Group. (2004) Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. International Journal of Hematology, 80, 267-277.
9. Ohmachi, K., Ando, K., Ogura, M., Uchida, T., Itoh, K., Kubota, N., Ishizawa, K., Yamamoto, J., Watanabe, T., Uike, N., Choi, I., Terui, Y., Usuki, K., Nagai, H., Uoshima, N., Tobinai, K. & Japanese Bendamustine Lymphoma Study Group. (2010) Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Science, 101, 2059-2064.
10. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M. & Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115.
11. Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L.H., Lerach, S., Tang, H., Ma, J., Rossi, D., Chadburn, A., Murty, V.V., Mullighan, C.G., Gaidano, G., Rabadan, R., Brindle, P.K. & Dalla-Favera, R. (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature, 471, 189-195.
12. Relander, T., Johnson, N.A., Farinha, P., Connors, J.M., Sehn, L.H. & Gascoyne, R.D. (2010) Prognostic factors in follicular lymphoma. Journal of Clinical Oncology, 28, 2902-2913.
13. Rummel, M.J., Niederle, N., Maschmeyer, G., Banat, G.A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., Kaiser, U., Weidmann, E., Dürk, H., Ballo, H., Stauch, M., Roller, F., Barth, J., Hoelzer, D., Hinke, A., Brugger, W. & Study group indolent Lymphomas (StiL). (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet, 381, 1203-1210.
14. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC, Lyon.
15. Tobinai, K., Watanabe, T., Ogura, M., Morishima, Y., Ogawa, Y., Ishizawa, K., Minami, H., Utsunomiya, A., Taniwaki, M., Terauchi, T., Nawano, S., Matsusako, M., Matsuno, Y., Nakamura, S., Mori, S., Ohashi, Y., Hayashi, M., Seriu, T. & Hotta, T. (2006) Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 24, 174-180.
16. Tobinai, K., Ogura, M., Itoh, K., Kinoshita, T., Hotta, T., Watanabe, T., Morishima, Y., Igarashi, T., Terauchi, T., Ohashi, Y. & All Collaborators of the IDEC-C2B8 Study Group in Japan. (2010) Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Cancer Science, 101, 2579-2585.
17. Warrener, R., Beamish, H., Burgess, A., Waterhouse, N.J., Giles, N., Fairlie, D. & Gabrielli, B. (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB Journal, 17, 1550-1552.
18. Watanabe, T., Kato, H., Kobayashi, Y., Yamasaki, S., Morita-Hoshi, Y., Yokoyama, H., Morishima, Y., Ricker, J.L., Otsuki, T., Miyagi-Maesima, A., Matsuno, Y. & Tobinai, K. (2010) Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Science, 101, 196-200.
19. Watanabe, T., Tobinai, K., Shibata, T., Tsukasaki, K., Morishima, Y., Maseki, N., Kinoshita, T., Suzuki, T., Yamaguchi, M., Ando, K., Ogura, M., Taniwaki, M., Uike, N., Takeuchi, K., Nawano, S., Terauchi, T. & Hotta, T. (2011) Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. Journal of Clinical Oncology, 29, 3990-3998.
20. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., Pohlman, B.L., Bartlett, N.L., Wiseman, G.A., Padre, N., Grillo-López, A.J., Multani, P. & White, C.A. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 2453-2463.